Breaking News Instant updates and real-time market news.

IOVA

Iovance Biotherapeutics

$7.15

-1.4 (-16.37%)

19:46
09/20/17
09/20
19:46
09/20/17
19:46

Iovance Biotherapeutics 7.69M share Secondary priced at $6.50

The deal priced at $6.50, below today's closing price of $7.15, which was a decline of over 16% on the trading day. Iovance Biotherapeutics intends to use the net proceeds from this offering to fund its current and future clinical trials for its product candidates, including its ongoing Phase 2 clinical trials of LN-144, TIL for treatment of metastatic melanoma, and LN-145, TIL for the treatment of cervical and head and neck cancers, to fund activities related to commercial scale-up of the company's TIL product manufacturing operations; and for working capital and other general corporate purposes. Jefferies and Wells Fargo acted as joint book running managers for the offering.

  • 25

    Sep

  • 21

    Sep

IOVA Iovance Biotherapeutics
$7.15

-1.4 (-16.37%)

08/03/17
OPCO
08/03/17
INITIATION
Target $13
OPCO
Outperform
Iovance Biotherapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Mark Breidenbach initiated Iovance Biotherapeutics with an Outperform and a $13 price target saying its tumor infiltrating lymphocytes therapy has been clinically validated by several academic institutions and expects to see a stream of clinical readouts from three ongoing company-sponsored trials in the next 12-18 month. Breidenbach expects lovance's path to commercialization in solid tumors to be simplified due to to the trailblazing of personalized CAR-T therapies for blood cancers.
08/31/17
HCWC
08/31/17
NO CHANGE
Target $16
HCWC
Buy
Iovance 'fired another shot across the bow of CAR-Ts,' says H.C. Wainwright
The approval of Novartis' (NVS) Kymriah is a "major leap forward" for oncology and immunotherapy, but there remains "significant room for differentiated products," H.C. Wainwright analyst Joseph Pantginis tells investors in a research note on Iovance Biotherapeutics (IOVA) titled "Pins Set Up: Kite Acquired and Kymriah Approved; TILs Can Knock 'Em Down; Reiterate Buy." The analyst believes Iovance's TILs, or tumor infiltrating lymphocytes, could be significantly differentiated from CAR-Ts like Kymriah. He says the TIL platform has a "significantly" more benign safety profile relative to CAR-Ts and growing evidence that it could effectively target solid tumors, an area where he thinks CAR-Ts continue to struggle. Pantginis thinks Iovance "fired another shot across the bow of CAR-Ts" with last night's ESMO conference abstracts. The company released preliminary data that it can generate highly active TILs from lymphoma tumors, the analyst contends. He reiterates a Buy rating on Iovance with a $16 price target. The shares closed yesterday down 30c to $5.55.
09/01/17
WELS
09/01/17
NO CHANGE
WELS
Outperform
Iovance fast track designation 'particularly validating,' says Wells Fargo
Wells Fargo analyst Jim Birchenough views Iovance Biotherapeutics' fast track designation from the FDA for its tumor infiltrating lymphocyte product LN-144 as "particularly validating for a novel cell therapy." The designation establishes unmet need for patients and could support a "more reasonable" Phase 3 hurdle, Birchenough tells investors in a research note. He has an Outperform rating on Iovance.
09/13/17
HCWC
09/13/17
NO CHANGE
Target $16
HCWC
Buy
Iovance expanding on multiple fronts, says H.C. Wainwright
Iovance Biotherapeutics released data at ESMO that it can generate highly active tumor infiltrating lymphocytes from lymphoma tumors, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note titled "Targeting Liquid Tumors and Automating the Supply Chain; Iovance Expanding on Multiple Fronts." The analyst says that while clinical efficacy of these expanded TILs remains unknown, he sees "significant safety profile differentiation" when compared to CAR-Ts. He notes that Iovance is also building new partnerships to make the supply chain run more efficiently. Pantginis keeps a Buy rating on the shares with a $16 price target.

TODAY'S FREE FLY STORIES

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:15
02/19/18
02/19
22:15
02/19/18
22:15
Downgrade
Teck Resources rating change at Macquarie »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:14
02/19/18
02/19
22:14
02/19/18
22:14
Downgrade
Teck Resources rating change at Macquarie »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:14
02/19/18
02/19
22:14
02/19/18
22:14
Downgrade
Teck Resources rating change at Macquarie »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.75

-0.58 (-1.91%)

22:14
02/19/18
02/19
22:14
02/19/18
22:14
Downgrade
Teck Resources rating change at Macquarie »

Teck Resources downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$305.63

18.98 (6.62%)

22:13
02/19/18
02/19
22:13
02/19/18
22:13
Upgrade
Chipotle rating change at Stifel »

Chipotle upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMG

Chipotle

$305.63

18.98 (6.62%)

22:12
02/19/18
02/19
22:12
02/19/18
22:12
Upgrade
Chipotle rating change at Stifel »

Chipotle upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

H

Hyatt

$79.73

-0.02 (-0.03%)

22:09
02/19/18
02/19
22:09
02/19/18
22:09
Upgrade
Hyatt rating change at Evercore ISI »

Hyatt upgraded to In Line…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

H

Hyatt

$79.73

-0.02 (-0.03%)

22:09
02/19/18
02/19
22:09
02/19/18
22:09
Upgrade
Hyatt rating change at Evercore ISI »

Hyatt upgraded to In Line…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

FLS

Flowserve

$44.05

1.18 (2.75%)

22:07
02/19/18
02/19
22:07
02/19/18
22:07
Upgrade
Flowserve rating change at RBC Capital »

Flowserve upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

FLS

Flowserve

$44.05

1.18 (2.75%)

22:07
02/19/18
02/19
22:07
02/19/18
22:07
Upgrade
Flowserve rating change at RBC Capital »

Flowserve upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

, SNY

Sanofi

$39.91

0.19 (0.48%)

20:02
02/19/18
02/19
20:02
02/19/18
20:02
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

SNY

Sanofi

$39.91

0.19 (0.48%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNAP

Snap

$20.42

0.67 (3.39%)

GE

General Electric

$15.05

0.2 (1.35%)

DIS

Disney

$106.53

1.35 (1.28%)

GOOG

Alphabet

$1,094.80

5.28 (0.48%)

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

LRCX

Lam Research

$187.91

2.2 (1.18%)

C

Citi

$76.82

-0.26 (-0.34%)

CMI

Cummins

$165.60

0.58 (0.35%)

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

WMT

Walmart

$104.78

1.55 (1.50%)

PFE

Pfizer

$36.26

0.55 (1.54%)

CSCO

Cisco

$44.33

0.25 (0.57%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

PEP

PepsiCo

$111.06

0.09 (0.08%)

MMM

3M

$236.67

1.8 (0.77%)

BMY

Bristol-Myers

$68.96

-0.02 (-0.03%)

UTX

United Technologies

$129.26

-0.74 (-0.57%)

TXN

Texas Instruments

$104.47

-0.1 (-0.10%)

ABT

Abbott

$60.17

0.67 (1.13%)

HOV

Hovnanian

$2.24

0.12 (5.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 23

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 13

    Mar

  • 18

    Mar

  • 25

    Mar

  • 28

    Mar

  • 29

    Mar

  • 29

    Mar

  • 04

    Apr

  • 13

    Apr

  • 23

    Apr

  • 02

    May

  • 03

    May

  • 30

    May

  • 14

    Jul

  • 12

    Oct

CUB

Cubic

19:34
02/19/18
02/19
19:34
02/19/18
19:34
Hot Stocks
Cubic names president, CEO Bradley Feldmann as Chairman of the Board »

Cubic Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

  • 06

    Mar

  • 07

    Mar

  • 08

    Mar

  • 14

    Jun

HCLP

Hi-Crush Partners

$12.40

0.25 (2.06%)

19:10
02/19/18
02/19
19:10
02/19/18
19:10
Earnings
Breaking Earnings news story on Hi-Crush Partners »

Hi-Crush Partners expects…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

HCLP

Hi-Crush Partners

$12.40

0.25 (2.06%)

19:08
02/19/18
02/19
19:08
02/19/18
19:08
Earnings
Hi-Crush Partners reports Q4 diluted EPS 47c, consensus 51c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

  • 28

    Feb

FSS

Federal Signal

$19.40

0.15 (0.78%)

19:04
02/19/18
02/19
19:04
02/19/18
19:04
Hot Stocks
Federal Signal declares dividend of 7c per share »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCE

BCE

$44.49

-0.02 (-0.04%)

19:03
02/19/18
02/19
19:03
02/19/18
19:03
Hot Stocks
BCE reports results of Series AC, AD Preferred Share conversions »

BCE announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PRGX

PRGX Global

$7.95

0.35 (4.61%)

18:38
02/19/18
02/19
18:38
02/19/18
18:38
Hot Stocks
PRGX Global announces appointment of new Chief Product Officer »

PRGX Global announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

CRMT

America's Car-Mart

$46.25

0.6 (1.31%)

18:37
02/19/18
02/19
18:37
02/19/18
18:37
Earnings
America's Car-Mart reports Q3 revenue $$147M, consensus $136.24M »

Reports Q3 $1.82 per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

TAX

Liberty Tax

18:30
02/19/18
02/19
18:30
02/19/18
18:30
Hot Stocks
Liberty Tax Service taps Nicole Ossenfort to be CEO »

Liberty Tax, the parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAX

Liberty Tax

18:29
02/19/18
02/19
18:29
02/19/18
18:29
Hot Stocks
Shaun York to be Chief Operating Officer for Liberty Tax Service »

Liberty Tax, the parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAX

Liberty Tax

18:28
02/19/18
02/19
18:28
02/19/18
18:28
Hot Stocks
Liberty Tax names Ryan Dodson Chief Strategy Officer »

Liberty Tax, the parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLX

Helix Energy

18:27
02/19/18
02/19
18:27
02/19/18
18:27
Earnings
Helix Energy reports Q4 EPS 34c, may not compare consensus (1C) »

Reports Q4 revenue $163M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

EMES

Emerge Energy

$7.77

0.12 (1.57%)

, CNI

Canadian National

$76.18

-0.68 (-0.88%)

18:17
02/19/18
02/19
18:17
02/19/18
18:17
Hot Stocks
Emerge Energy Services responds to industry-wide railroad service issues »

Emerge Energy Services…

EMES

Emerge Energy

$7.77

0.12 (1.57%)

CNI

Canadian National

$76.18

-0.68 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 28

    Feb

WM

Waste Management

$85.15

1.13 (1.34%)

18:09
02/19/18
02/19
18:09
02/19/18
18:09
Hot Stocks
Waste Management announces cash dividend »

Waste Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRK.A

Berkshire Hathaway

$306,000.00

1.01 (0.00%)

, BRK.B

Berkshire Hathaway

$203.79

-0.11 (-0.05%)

18:07
02/19/18
02/19
18:07
02/19/18
18:07
Hot Stocks
JM announces Eric Cremer as New Chief Human Resources Officer »

Johns Manville, a…

BRK.A

Berkshire Hathaway

$306,000.00

1.01 (0.00%)

BRK.B

Berkshire Hathaway

$203.79

-0.11 (-0.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.